Terapia trombolítica del infarto cerebral agudo. Primer año de experiencia en Panamá 2003-2004.
[Terapia trombolítica del infarto cerebral agudo. Primer año de experiencia en Panamá 2003-2004.]Victor C Urrutia1, Aron Benzadón2, Ana C Arango2
1. Neurólogos Asociados S,A.; 2. Neurólogos Asociados, S.A..
Descargas
Resumen
RESUMEN:
La enfermedad cerebrovascular es la tercera causa de muerte en Panamá. Se presentan las indicaciones, contraindicaciones y protocolo para el uso del activador del plasminógeno tisular recombinante (rt-PA) como tratamiento activo para el infarto cerebral. Se detallan los dos primeros pacientes tratados en Panamá con esta terapia.
SUMMARY: The cerebrovascular disease (CVD) is the third cause of death in Panama. We
present the indications, contraindications and the protocol for the use of the activator of the
recombinant tissue plasminogen activator, as an active treatment for the cerebral impact. We bring
the details of the first two patients treated in Panama with this therapy.
Palabras clave: Enfermedad cerebrovascular, isquemia cerebral, infarto cerebral, terapia
Abstract
RESUMEN:
La enfermedad cerebrovascular es la tercera causa de muerte en Panamá. Se presentan las indicaciones, contraindicaciones y protocolo para el uso del activador del plasminógeno tisular recombinante (rt-PA) como tratamiento activo para el infarto cerebral. Se detallan los dos primeros pacientes tratados en Panamá con esta terapia.
SUMMARY: The cerebrovascular disease (CVD) is the third cause of death in Panama. We
present the indications, contraindications and the protocol for the use of the activator of the
recombinant tissue plasminogen activator, as an active treatment for the cerebral impact. We bring
the details of the first two patients treated in Panama with this therapy.
Palabras clave: Enfermedad cerebrovascular, isquemia cerebral, infarto cerebral, terapia
Citas
[1] Departamento de Análisis de Situación y
[2] Tendencias de Salud, Sección de Estadísticas.
[4] Sacco RL, Benjamín EJ, Broderick JP, et al: Risk
[5] Factors Panel-American Heart Association Prevention
[6] Conference IV. Stroke. 1997; 28:1507-1517.
[7] Broderick J, Brott T, Kothari R, et al: The Greater
[8] Cincinnati/Northern Kentucky Stroke Study:
[9] Preliminary first-ever and total incidence rates of
[10] strokes among blacks. Stroke. 1998; 29:415-421.
[11] Pasternak RC, Criqui MH, Benjamin EJ, Fowkes
[12] FGR, Isselbacher EM, et al: Atherosclerotic
[13] Vascular Disease Conference, Writing Group I:
[14] Epidemiology. Circulation. 2004; 109:2605-2612.
[15] Saposnik G, Del Brutto OH: Sociedad
[16] Iberoamericana de Enfermedades
[17] Cerebrovasculares. Stroke in South America. A
[18] systematic review of incidente, prevalence, and
[19] stroke subtypes. Stroke. 2003; 34:2103-2108.
[20] Sacco RL, Boden-Albala B, Gan R, Chen X,
[21] Kargman DE, et al: Stroke incidence among white,
[22] black, and Hispanic residents of an urban community:
[23] The Northern Manhattan Stroke Study. American
[24] Journal of Epidemiology. 1998; 147(3):259-268.
[25] The National Institute of Neurological Disorders and
[26] Stroke r-tPA Stroke Study Group. Tissue plasminogen
[27] activator for acute ischemic stroke. N Engl J
[29] Hacke W, Brott T, Caplan LR, et al: Thrombolysis in
[30] acute ischemic stroke: Controlled trials and clinical
[31] experience. Neurology. 1999; 53(suppl):S3-S14.
[32] Buchan AM, Barber PA, Newcommon N, Karbalai
[33] HG, Demchuk AM, Hoyte KM, Klein GM, Feasby
[34] TE: Effectiveness of t-PA in acute ischemic stroke,
[35] Outcome relates to appropriateness. Neurology.
[37] Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E,
[38] Zurrú C, Biller J: Protocol violations in communitybased
[39] rt-PA stroke treatment are associated with
[40] symptomatic intracerebral hemorrhage. Neurology.
[42] Adams HP, Adams RJ, Brott T, del Zoppo GJ,
[43] Furlan A, et al: Guidelines for the early management
[44] of patients with ischemic stroke, a scientific
[45] statement from the stroke council of the American
[46] Stroke Association. Stroke. 2003; 34:1056-1083.
[47] Albers GW, Bates VE, Clark WM, et al: Intravenous
[48] tissue-type plasminogen activator for the
[49] treatment of acute stroke: The Standard Treatment
[50] with Activase to Reverse Stroke (STARS) study.
[51] JAMA. 2000; 283:1145-1150.
[52] Katzman IL, Furlan AJ, Lloyd Le, Frank JI, Harper
[53] DL, et al: Use of tissue-type plasminogen activator
[54] for acute ischemic stroke, the Cleveland area
[55] experience. JAMA. 2000; 283:1151-58.
[56] Joint Commission on Accreditation of Healthcare
[57] Organizations. Primary Stroke Center Certification.
[58] Fagan S, Morgenstern L, Pettita A, Ward RE, Tilley
[59] BC, et al: Cost-effectiveness of tissue plasminogen
[60] activator for acute ischaemic stroke. Neurology.
[62] Sandercock P, Berge E, Dennis M, Forbes J, Hand
[63] P, et al: Cost-effectiveness of thrombolysis with
[64] recombinant tissue plasminogen activator for acute
[65] ischemic stroke assessed by a model based on UK
[66] NHS costs. Stroke. 2004; 35:1490-1498.
[67] Jorgensen HS, Kammersgaard LP, Houth J,
[68] Nakayama H, Raaschou HO, et al: Who benefits
[69] from treatment and rehabilitation in a stroke unit? : A
[70] community-based study. Stroke. 2000; 31:434-439.
[71] Jørgensen HS, Kammersgaard LP, Nakayama H,
[72] Raaschou HO,Larsen K, et al: Treatment and
[73] Rehabilitation on a Stroke Unit Improves 5-Year
[74] Survival: A Community-Based Study. Stroke.1999;
[76] Evans A, Harraf F, Donaldson N, Kalra L: Randomized
[77] controlled study of stroke unit care versus
[78] stroke team care in different stroke subtypes.
[79] Stroke. 2002; 33:449-455.
[80] Lewandowski CA, Frankel M, Tomsick TA,
[81] Broderick J, Frey J, the EMS Bridging Trial Investigators:
[82] Combined intravenous and intra-arterial rt-
[83] PA versus intra-arterial therapy of acute ischemic
[84] stroke. Stroke; 30:2598-2605.
[85] Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D,
[86] et al: Combined intravenous and intra-arterial
[87] recombinant tissue plasminogen activator in acute
[88] ischemic stroke. Stroke. 2000; 31:2552-2557.
[89] Shaltoni HM, Noser EA, Hall CE, Ireland JK,
[90] Wojner AW, et al: How safe is intra-arterial thrombolysis
[91] following full-dose (0.9mg/kg) intravenous
[92] TPA? Abstract presentado en el 29th International
Licencia
Derechos autoriales y de reproducibilidad. La Revista Médica de Panama es un ente académico, sin fines de lucro, que forma parte de la Academia Panameña de Medicina y Cirugía. Sus publicaciones son de tipo acceso gratuito de su contenido para uso individual y académico, sin restricción. Los derechos autoriales de cada artículo son retenidos por sus autores. Al Publicar en la Revista, el autor otorga Licencia permanente, exclusiva, e irrevocable a la Sociedad para la edición del manuscrito, y otorga a la empresa editorial, Infomedic International Licencia de uso de distribución, indexación y comercial exclusiva, permanente e irrevocable de su contenido y para la generación de productos y servicios derivados del mismo. En caso que el autor obtenga la licencia CC BY, el artículo y sus derivados son de libre acceso y distribución.
